These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22036848)

  • 21. [The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
    Nicolau Ramis J; Masmiquel Comas L
    Endocrinol Nutr; 2012 Jan; 59(1):1-8. PubMed ID: 22177885
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment with new preparations against type 2 diabetes not sufficiently documented].
    Karlsson EA; Palmér M; Malmström R
    Lakartidningen; 2008 Feb 27-Mar 4; 105(9):647-8; author reply 648-9. PubMed ID: 18376713
    [No Abstract]   [Full Text] [Related]  

  • 23. ACP Journal Club. Review: in type 2 diabetes, dipeptidyl peptidase-4 inhibitors do not increase pancreatitis.
    Morey-Vargas OL; Montori VM
    Ann Intern Med; 2014 Jan; 160(2):JC8-9. PubMed ID: 24445718
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of type 2 diabetes with new oral antihyperglycaemic drugs].
    Seissler J
    MMW Fortschr Med; 2008 May; 150(18):27-31. PubMed ID: 18533605
    [No Abstract]   [Full Text] [Related]  

  • 25. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
    Engel SS; Williams-Herman DE; Golm GT; Clay RJ; Machotka SV; Kaufman KD; Goldstein BJ
    Int J Clin Pract; 2010 Jun; 64(7):984-90. PubMed ID: 20412332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
    Grunberger G
    J Diabetes; 2013 Sep; 5(3):241-53. PubMed ID: 23489968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®).
    Stricklin SM; Stoecker WV; Rader RK; Hood AF; Litt JZ; Schuman TP
    Dermatol Online J; 2012 Feb; 18(2):9. PubMed ID: 22398230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
    Singh S; Chang HY; Richards TM; Weiner JP; Clark JM; Segal JB
    JAMA Intern Med; 2013 Apr; 173(7):534-9. PubMed ID: 23440284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].
    Sjöholm A; Agardh CD; Brismar K; Efendic S; Eliasson B; Eriksson JW; Frid A; Groop L; Holmgren J; Ridderstråle M; Smith U
    Lakartidningen; 2008 Apr 23-May 6; 105(17-18):1310, 1312. PubMed ID: 18561535
    [No Abstract]   [Full Text] [Related]  

  • 30. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
    Viereck C; Boudes P
    Contemp Clin Trials; 2011 May; 32(3):324-32. PubMed ID: 21266202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The value of incretin based therapies].
    Gallwitz B
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
    Stafford S; Elahi D; Meneilly GS
    J Am Geriatr Soc; 2011 Jun; 59(6):1148-9. PubMed ID: 21668924
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment with DPP-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes.
    Shetty AS; Nandith A; Snehalath C; Ramachandran A
    J Assoc Physicians India; 2013 Aug; 61(8):543-4. PubMed ID: 24818338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
    de Heer J; Göke B
    Expert Opin Drug Saf; 2014 Nov; 13(11):1469-81. PubMed ID: 25270593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety of incretin based drug treatments for type 2 diabetes.
    Bolen SD; Maruthur NM
    BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
    [No Abstract]   [Full Text] [Related]  

  • 37. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
    Aroda VR; Ratner R
    Diabetes Metab Res Rev; 2011 Sep; 27(6):528-42. PubMed ID: 21484979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
    Nauck MA; Meier JJ; Schmidt WE
    Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
    [No Abstract]   [Full Text] [Related]  

  • 39. The safety of incretin based drugs.
    Montori VM
    BMJ; 2014 Apr; 348():g2779. PubMed ID: 24764568
    [No Abstract]   [Full Text] [Related]  

  • 40. ACP Journal Club. Incretin use was not associated with increased risk for acute pancreatitis.
    Schectman J
    Ann Intern Med; 2015 Jun; 162(12):JC12. PubMed ID: 26075777
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.